EMEA-002116-PIP01-17
Key facts
| Active substance |
Insulin human (NTRA-2112)
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0079/2018
|
| PIP number |
EMEA-002116-PIP01-17
|
| Pharmaceutical form(s) |
Powder for oral solution
|
| Condition(s) / indication(s) |
Treatment of intestinal malabsorption in preterm infants
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
ELGAN Pharma Ltd
Tel. +972 37262262 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|